Search

Your search keyword '"Fibbe, W. E."' showing total 389 results
Start Over Author "Fibbe, W. E."
389 results on '"Fibbe, W. E."'

1. Intramyocardial bone marrow cell injection does not lead to functional improvement in patients with chronic ischaemic heart failure without considerable ischaemia

Author

Mann, I., Tseng, C. C. S., Rodrigo, S. F., Koudstaal, S., van Ramshorst, J., Beeres, S. L., Dibbets-Schneider, P., de Geus-Oei, L. F., Lamb, H. J., Wolterbeek, R., Zwaginga, J. J., Fibbe, W. E., Westinga, K., Bax, J. J., Doevendans, P. A., Schalij, M. J., Chamuleau, S. A. J., and Atsma, D. E.

Published
2019
Full Text
View/download PDF

2. Bloedziekten

Author

Kluin-Nelemans, J. C., primary, Brand, A., additional, van der Meer, F. J. M., additional, Fibbe, W. E., additional, and Willemze, R., additional

Published
2016
Full Text
View/download PDF

12. Cord blood banking

Author

Brand, A., Rebulla, P., Engelfriet, C. P., Reesink, H. W., Beguin, Y., Baudoux, E., Kögler, G., Ebrahimi, M., Grazzini, G., Costa, A. Nanni, Bosi, A., Sacchi, N., Lombardini, L., Pupella, S., Lecchi, L., Calderón Garcidueñas, E. D., van Beckhoven, J. M., de Wit, H. J. C., Fibbe, W. E., Zhiburt, E. B., Bart, T., Beksaç, M., Navarrete, C., and Regan, F.

Published
2008

25. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry

Author

Farge, D, Passweg, J, van Laar, J M, Marjanovic, Z, Besenthal, C, Finke, J, Peter, H H, Breedveld, F C, Fibbe, W E, Black, C, Denton, C, Koetter, I, Locatelli, F, Martini, A, Schattenberg, A V N, van den Hoogen, F, van de Putte, L, Lanza, F, Arnold, R, Bacon, P A, Bingham, S, Ciceri, F, Didier, B, Diez-Martin, J L, Emery, P, Feremans, W, Hertenstein, B, Hiepe, F, Luosujärvi, R, Lara, A Leon, Marmont, A, Martinez, A M, Cascon, H Pascual, Bocelli-Tyndall, C, Gluckman, E, Gratwohl, A, and Tyndall, A

Published
2004

33. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

Author

Binks, M, Passweg, J R, Furst, D, McSweeney, P, Sullivan, K, Besenthal, C, Finke, J, Peter, H H, van Laar, J, Breedveld, F C, Fibbe, W E, Farge, D, Gluckman, E, Locatelli, F, Martini, A, van den Hoogen, F, van de Putte, L, Schattenberg, A V N, Arnold, R, Bacon, P A, Emery, P, Espigado, I, Hertenstein, B, Hiepe, F, Kashyap, A, Kötter, I, Marmont, A, Martinez, A, Pascual, M J, Gratwohl, A, Prentice, H G, Black, C, and Tyndall, A

Published
2001

39. Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model

Author

Thielen, F. W., Blommestein, H. M., Oosten, L. E. M., Calkoen, F. G., Lankester, A. C., Zwaginga, J. J., Le Blanc, K., Redondo, A., Sanchez-Guijo, F., Algeri, M., Locatelli, Franco, Fibbe, W. E., Uyl-de Groot, C. A., Locatelli F. (ORCID:0000-0002-7976-3654), Thielen, F. W., Blommestein, H. M., Oosten, L. E. M., Calkoen, F. G., Lankester, A. C., Zwaginga, J. J., Le Blanc, K., Redondo, A., Sanchez-Guijo, F., Algeri, M., Locatelli, Franco, Fibbe, W. E., Uyl-de Groot, C. A., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Objective: No standard second-line treatment exists for acute graft-versus-host disease steroid-refractory (SR-aGvHD), and long-term outcomes remain poor. Mesenchymal stromal cells (MSCs) have been evaluated as treatment, but no disease model (DM) exists that integrates and extrapolates currently available evidence. The aim of this study was to develop such a DM to describe the natural history of SR-aGvHD and to predict long-term outcomes. Method: The DM was developed in collaboration with experts in haematology-oncology. Subsequently, a model simulation was run. Input parameters for transition and survival estimates were informed by published data of clinical trials on MSC treatment for SR-aGvHD. Parametric distributions were used to estimate long-term survival rates after MSCs. Results: The newly developed DM is a cohort model that consists of eight health states. For the model simulation, we obtained data on 327 patients from 14 published phase II trials. Due to limited evidence, DM structure was simplified and several assumptions had to be made. Median overall survival was 3.2 years for complete response and 0.5 years for no complete response. Conclusion: The DM provides a comprehensive overview on the second-line treatment pathway for aGvHD and enables long-term predictions that can be used to perform a cost-effectiveness analysis comparing any treatment for SR-aGvHD.

Published
2018

41. Local injection of autologous bone marrow cells to regenerate muscle in patients with traumatic brachial plexus injury

Author

Hogendoorn, S., Duijnisveld, B. J., van Duinen, S. G., Stoel, B. C., van Dijk, J. G., Fibbe, W. E., and Nelissen, R. G. H. H.

Subjects
Autologous Bone Marrow Injection, Brachial Plexus, Partial Muscle Denervation, Upper Limb
Abstract

Objectives Traumatic brachial plexus injury causes severe functional impairment of the arm. Elbow flexion is often affected. Nerve surgery or tendon transfers provide the only means to obtain improved elbow flexion. Unfortunately, the functionality of the arm often remains insufficient. Stem cell therapy could potentially improve muscle strength and avoid muscle-tendon transfer. This pilot study assesses the safety and regenerative potential of autologous bone marrow-derived mononuclear cell injection in partially denervated biceps. Methods Nine brachial plexus patients with insufficient elbow flexion (i.e., partial denervation) received intramuscular escalating doses of autologous bone marrow-derived mononuclear cells, combined with tendon transfers. Effect parameters included biceps biopsies, motor unit analysis on needle electromyography and computerised muscle tomography, before and after cell therapy. Results No adverse effects in vital signs, bone marrow aspiration sites, injection sites, or surgical wound were seen. After cell therapy there was a 52% decrease in muscle fibrosis (p = 0.01), an 80% increase in myofibre diameter (p = 0.007), a 50% increase in satellite cells (p = 0.045) and an 83% increase in capillary-to-myofibre ratio (p < 0.001) was shown. CT analysis demonstrated a 48% decrease in mean muscle density (p = 0.009). Motor unit analysis showed a mean increase of 36% in motor unit amplitude (p = 0.045), 22% increase in duration (p = 0.005) and 29% increase in number of phases (p = 0.002). Conclusions Mononuclear cell injection in partly denervated muscle of brachial plexus patients is safe. The results suggest enhanced muscle reinnervation and regeneration. Cite this article: Bone Joint Res 2014;3:38–47.

Published
2014

42. Intramyocardial bone marrow cell injection does not lead to functional improvement in patients with chronic ischaemic heart failure without considerable ischaemia

Author

Mann, I., primary, Tseng, C. C. S., additional, Rodrigo, S. F., additional, Koudstaal, S., additional, van Ramshorst, J., additional, Beeres, S. L., additional, Dibbets-Schneider, P., additional, de Geus-Oei, L. F., additional, Lamb, H. J., additional, Wolterbeek, R., additional, Zwaginga, J. J., additional, Fibbe, W. E., additional, Westinga, K., additional, Bax, J. J., additional, Doevendans, P. A., additional, Schalij, M. J., additional, Chamuleau, S. A. J., additional, and Atsma, D. E., additional

Published
2018
Full Text
View/download PDF

48. The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem-cell mobilization

Author

Fibbe, W. E., Pruijt, J. F. M., Kooyk, Y., Carl Figdor, Opdenakker, G., and Willemze, R.

Subjects
Tumorimmunology
Abstract

The chemokine interleukin-8 (IL-8) is a potent chemoattractant and activator of neutrophils. Upon systemic injection, IL-8 induces an immediate neutropenia followed by a rebound granulocytosis. In this report, we discuss the effects of IL-8 on the mobilization of hematopoietic stem cells. Within 20 minutes following a single intraperitoneal injection in mice, IL-8 induces the mobilization of hematopoietic progenitor cells (HPC) with colony-forming, radioprotective, and long-term lymphomyeloid resubpopulating ability. Mobilization can be specifically prevented by pretreatment with antibodies against the beta2 integrin LFA-1 (CD11a). In monkeys, IL-8 Induces the rapid release of the metalloproteinase gelatinase-B concurrent with the mobilization of HPC. The latter effect can be prevented by blocking gelatinase-B activity using specific monoclonal antibodies, suggesting the involvement of gelatinase-B as a mediator of HPC mobilization. These results are consistent with the hypothesis that neutrophils are major regulators of stem-cell mobilization through the release of metalloproteinases (MMPs) that cleave extracellular matrix molecules to which HPC are attached.

Published
2000

49. Murine hematopoietic progenitor cells with colony-forming or radioprotective capacity lack expression of the beta(2) integrin LFA-1

Author

Pruijt, J F, van Kooyk, Y, Figdor, C G, Willemze, R, Fibbe, W E, Molecular cell biology and Immunology, CCA - Cancer biology and immunology, AII - Cancer immunology, AII - Inflammatory diseases, and Dermatology

Abstract

Recently, we have demonstrated that antibodies that block the function of the beta2-integrin leukocyte function-associated antigen-1 (LFA-1) completely abrogate the rapid mobilization of hematopoietic progenitor cells (HPC) with colony-forming and radioprotective capacity induced by interleukin-8 (IL-8) in mice. These findings suggested a direct inhibitory effect of these antibodies on LFA-1-mediated transmigration of stem cells through the bone marrow endothelium. Therefore, we studied the expression and functional role of LFA-1 on murine HPC in vitro and in vivo. In steady state bone marrow +/- 50% of the mononuclear cells (MNC) were LFA-1(neg). Cultures of sorted cells, supplemented with granulocyte colony-stimulating factor (G-CSF)/granulocyte-macrophage colony-stimulating factor (GM-CSF)/IL-1/IL-3/IL-6/stem cell factor (SCF) and erythropoietin (EPO) indicated that the LFA-1(neg) fraction contained the majority of the colony-forming cells (CFCs) (LFA-1(neg) 183 +/- 62/7,500 cells v LFA-1(pos) 29 +/- 17/7,500 cells, P

Published
1999

Catalog

Books, media, physical & digital resources
See catalog results